Drug interactions of new oral anticoagulants: Inside and outside table cells

Abstract

The opinion is expressed in some domestic publications that rivaroxaban has the most favorable profile of drug interaction in comparison with other new oral anticoagulants (NOAC). The basis for such judgments is the summary table of drug interaction from the Guidelines of the European Heart Rhythm Association 2015 on the use of NOAC in patients with non-valvular atrial fibrillation. The paper discusses the issue that the abovementioned table contains some incorrect qualitative statements and quantitative data inconsistent with primary source of information of NOAC drug interactions, and provides the updated and extended information on changes in NOAC plasma concentrations when co-administered with drugs from the other groups. On the basis of the presented data, the authors come to the conclusion that the profile of drug interaction of rivaroxaban does not differ significantly from these of the other NOAC.